How likely are my patients to be covered for DUPIXENT?

99% of commercial AD patients (6+ months of age) nationally are covered for DUPIXENT, with 91% of commercial AD patient lives having to fail only 1 or 2 prescription topical treatments.^2,a

^a MMIT Analysis, June 2024. Analysis included DUPIXENT, tralokinumab, upadacitinib, and abrocitinib.